A Test in Context: Neprilysin: Function, Inhibition, and Biomarker

172Citations
Citations of this article
125Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Neprilysin is a zinc-dependent endopeptidase. It is ubiquitous in distribution and promiscuous in function, with >50 putative peptide substrates with varying levels of in vitro and/or in vivo evidence of functional relevance. In the first part of this review, we discuss the genetic, structural, substrate, and pathophysiological aspects of neprilysin. We incorporate information provided by genetically modified models, as well as pre-clinical and clinical data from investigations of synthetic neprilysin inhibitors. We next highlight the value of neprilysin as a biotarget and weigh the clinical benefits of synthetic neprilysin inhibitors, either alone or in combination with antagonists of the renin–angiotensin system. Finally, we provide evidence about soluble neprilysin as a biomarker surrogate in patients with heart failure and identify important gaps that require further research before soluble neprilysin is used clinically. In sum, neprilysin is a versatile, veteran player returning yet again to center stage after an eventful career spanning >40 years.

Cite

CITATION STYLE

APA

Bayes-Genis, A., Barallat, J., & Richards, A. M. (2016, August 9). A Test in Context: Neprilysin: Function, Inhibition, and Biomarker. Journal of the American College of Cardiology. Elsevier USA. https://doi.org/10.1016/j.jacc.2016.04.060

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free